Contract analysis

I. Executive Summary The purpose of this memorandum is to assess the entitlement of our client, Optiwave Semiconductor Corp. ("OWS"), to a permanent injunction against Lumicore Technologies, Inc. ("Lumicore") under the four-factor framework established by the Supreme Court in Northgate Group v. MercExchange, L.L.C., 547 U.S. 388 (2006), following what we anticipate will be a favorable outcome on the merits at trial.

1. Optiwave Semiconductor Corp. ("OWS") Optiwave Semiconductor Corp. is a Delaware corporation headquartered at 4810 Bayside Technology Parkway, Suite 300, Santa Clara, California 95054. Founded in 2011 by Dr. Priya Ramaswamy and Dr. Jian-Wei Huang, OWS is a fabless semiconductor company specializing in the design and commercialization of silicon photonics chipsets for data-center interconnects. The company has grown

2. Lumicore Technologies, Inc. ("Lumicore") Lumicore Technologies, Inc. is a Delaware corporation headquartered at 9200 Spectrum Boulevard, Building C, Austin, Texas 78759. Founded in 2015, Lumicore is a fast-growing entrant in the silicon-photonics transceiver market, targeting both hyperscale data-center and telecommunications applications. The company currently employs approximately 870 people and has expanded rap

1. The Asserted Patents OWS asserts four utility patents in this action, each directed to a distinct aspect of silicon-photonic transceiver technology: The '847 Patent (U.S. Patent No. 10,234,847), entitled "Multi-Channel Silicon Photonic Waveguide Multiplexer with Low Insertion Loss," was filed on September 14, 2016, and issued on March 19, 2019. The original assignee is OWS. The '847 Patent claims a novel waveguide

2. The Accused Products OWS accuses three Lumicore transceiver module product lines of infringement: The total projected accused-product revenue from Lumicore's initial launch of the LumiLink 400G-ZR+ in Q3 2022 through the anticipated trial date in Q4 2025 is approximately $714.6 million. Notably, the accused product lines constitute a very substantial share of Lumicore's total revenue — approximately 85% of Lumicor

III. Legal Framework: The *Cascade Holdings* Four-Factor Test In Northgate Group v. MercExchange, L.L.C., 547 U.S. 388 (2006), the Supreme Court held that the traditional four-factor test for permanent injunctive relief applies in patent cases, just as it does in other areas of equity. The Court rejected the Federal Circuit's prior rule that a permanent injunction should issue as a matter of course following a findin

1. That it has suffered an irreparable injury;

2. That remedies available at law, such as monetary damages, are inadequate to compensate for that injury;

3. That, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and

4. That the public interest would not be disserved by a permanent injunction. Id. at 391. Each factor must be analyzed on its own facts; the Court emphasized that courts should not adopt "categorical" rules that either always grant or always deny injunctive relief upon a finding of infringement. Id. at 393–94. In the years since Cascade Holdings, the Federal Circuit and district courts have developed a substantial bo

IV. Factor 1: Irreparable Harm The first and most significant Cascade Holdings factor asks whether OWS has suffered — and continues to suffer — irreparable injury as a result of Lumicore's infringement. Our analysis demonstrates that OWS has a strong showing of irreparable harm across multiple, interrelated dimensions: direct competition and market-share erosion, price erosion, loss of customer relationships and desi

V. Factor 2: Inadequacy of Legal Remedies The second Cascade Holdings factor requires OWS to demonstrate that remedies available at law — principally monetary damages — are inadequate to compensate for the injury caused by Lumicore's infringement. This factor is closely related to the first factor and, as discussed below, is strongly supported by the same evidence. A. Ongoing Nature of the Harm Monetary damages, no m

VI. Factor 3: Balance of Hardships The third Cascade Holdings factor requires the Court to consider the balance of hardships between the parties in determining whether equitable relief is warranted. As analyzed below, the balance tips decidedly in favor of OWS. A. Hardship to OWS Absent an Injunction The hardship to OWS if the Court declines to issue a permanent injunction is severe and ongoing. Every day that Lumico

VII. Factor 4: Public Interest The fourth and final Cascade Holdings factor asks whether the public interest would be disserved by a permanent injunction. Our analysis concludes that the public interest affirmatively supports the issuance of a permanent injunction in this case. A. Patent System Integrity The public has a strong interest in a robust patent system that incentivizes innovation and rewards those who inve

VIII. Potential Counterarguments and Responses In anticipation of the arguments that Lumicore is likely to raise in opposition to OWS's request for a permanent injunction, we analyze each potential counterargument and set forth our recommended responses. A. Lumicore Will Argue It Does Not Infringe (No Likelihood of Prevailing) Anticipated Argument: Lumicore may argue that it does not infringe the asserted patents and